Jacobio Pharmaceuticals

Executive Summary

Jacobio Pharmaceuticals is a clinical-stage oncology company based in Beijing, China, specializing in small molecule drugs targeting difficult-to-drug cancer pathways, particularly KRAS mutations. Its lead asset, JAB-21822, a KRAS G12C inhibitor, is in Phase 2/3 trials for non-small cell lung cancer (NSCLC) and has shown promising efficacy and safety. The company also develops JAB-3312, a SHP2 inhibitor, in combination with JAB-21822 to address resistance. With an integrated R&D platform and a pipeline including KRAS G12D inhibitors, Jacobio emphasizes combination therapies to improve outcomes. Key catalysts include potential registrational data for JAB-21822, combination trial updates, and early-stage progress, positioning the company as a significant player in precision oncology.

Upcoming Catalysts (preview)

• Q3 2026JAB-21822 registrational data in NSCLC70% success
• Q4 2026JAB-3312 phase 1/2 combination data60% success
• Q2 2026IND filing for next-generation KRAS inhibitor80% success